Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure

J. H. Odom, B. D. Lowes, T. S. Crisman, D. A. Ferguson, E. E. Wolfel, J. Lindenfeld, M. R. Bristow, R. W. Schrier, W. T. Abraham

Research output: Contribution to journalArticle

Abstract

The systemic hemodynamic response to a continuous 4-hour infusion of human brain natriuretic peptide (hBNP) was determined in 12 patients with advanced NYHA class III heart failure. Seven patients had ischemic cardiomyopathy, while 5 patients had idiopathic dilated cardiomyopathy. The mean (± SEM) left ventricular ejection fraction for the group was 17 ± 2% (range 14-30%). Patients were evaluated during three 4-hour study periods: baseline, hBNP infusion (0.025 or 0.05 μg/kg/min), and post-treatment (recovery). During the study periods, urinary volume losses were replaced hourly with 0.45% saline solution to separate the vasodilatory and diuretic effects of hBNP. The systemic hemodynamic effects of hBNP in these heart failure patients is shown below (mean±SEM; *p<0.05, **p<0.01 vs. baseline). hBNP 0.025 (n=6) hBNP 0.05 (n=6) Baseline hBNP Recovery Baseline hBNP Recovery RAP (mmHg) 12±2 7±1** 8±1 15±2 10±2* 14±1 PCWP (mmHg) 25±5 12±2** 18±3 29±2 18±3** 24± SVR (d·sec/cm5) 1687±206 1357±160 1737±291 1854±232 1105±193** 1332±198 CI (L/min/m2) 1.96±0.2 2.15±0.2 1.84±0.2 1.68±0.2 2.32±0.3** 2.14±0.3 HR (BPM) 78±6 84±4 86±6 92±5 86±8** 87±9 Conclusion: This first study of a steady-state infusion of hBNP in patients with heart failure demonstrates that hBNP is pharmacologically active and has potential in the treatment of heart failure.

Original languageEnglish (US)
Pages (from-to)149A
JournalJournal of Investigative Medicine
Volume44
Issue number1
StatePublished - Jan 1 1996

Fingerprint

Brain Natriuretic Peptide
Hemodynamics
Heart Failure
Recovery
Dilated Cardiomyopathy
Treatment Failure
Cardiomyopathies
Diuretics
Sodium Chloride
Stroke Volume
Scanning electron microscopy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure. / Odom, J. H.; Lowes, B. D.; Crisman, T. S.; Ferguson, D. A.; Wolfel, E. E.; Lindenfeld, J.; Bristow, M. R.; Schrier, R. W.; Abraham, W. T.

In: Journal of Investigative Medicine, Vol. 44, No. 1, 01.01.1996, p. 149A.

Research output: Contribution to journalArticle

Odom, JH, Lowes, BD, Crisman, TS, Ferguson, DA, Wolfel, EE, Lindenfeld, J, Bristow, MR, Schrier, RW & Abraham, WT 1996, 'Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure', Journal of Investigative Medicine, vol. 44, no. 1, pp. 149A.
Odom, J. H. ; Lowes, B. D. ; Crisman, T. S. ; Ferguson, D. A. ; Wolfel, E. E. ; Lindenfeld, J. ; Bristow, M. R. ; Schrier, R. W. ; Abraham, W. T. / Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure. In: Journal of Investigative Medicine. 1996 ; Vol. 44, No. 1. pp. 149A.
@article{53dbe6a551f04f9bacdc270e502eae59,
title = "Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure",
abstract = "The systemic hemodynamic response to a continuous 4-hour infusion of human brain natriuretic peptide (hBNP) was determined in 12 patients with advanced NYHA class III heart failure. Seven patients had ischemic cardiomyopathy, while 5 patients had idiopathic dilated cardiomyopathy. The mean (± SEM) left ventricular ejection fraction for the group was 17 ± 2{\%} (range 14-30{\%}). Patients were evaluated during three 4-hour study periods: baseline, hBNP infusion (0.025 or 0.05 μg/kg/min), and post-treatment (recovery). During the study periods, urinary volume losses were replaced hourly with 0.45{\%} saline solution to separate the vasodilatory and diuretic effects of hBNP. The systemic hemodynamic effects of hBNP in these heart failure patients is shown below (mean±SEM; *p<0.05, **p<0.01 vs. baseline). hBNP 0.025 (n=6) hBNP 0.05 (n=6) Baseline hBNP Recovery Baseline hBNP Recovery RAP (mmHg) 12±2 7±1** 8±1 15±2 10±2* 14±1 PCWP (mmHg) 25±5 12±2** 18±3 29±2 18±3** 24± SVR (d·sec/cm5) 1687±206 1357±160 1737±291 1854±232 1105±193** 1332±198 CI (L/min/m2) 1.96±0.2 2.15±0.2 1.84±0.2 1.68±0.2 2.32±0.3** 2.14±0.3 HR (BPM) 78±6 84±4 86±6 92±5 86±8** 87±9 Conclusion: This first study of a steady-state infusion of hBNP in patients with heart failure demonstrates that hBNP is pharmacologically active and has potential in the treatment of heart failure.",
author = "Odom, {J. H.} and Lowes, {B. D.} and Crisman, {T. S.} and Ferguson, {D. A.} and Wolfel, {E. E.} and J. Lindenfeld and Bristow, {M. R.} and Schrier, {R. W.} and Abraham, {W. T.}",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "44",
pages = "149A",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Systemic hemodynamic effects of a steady-state infusion of human brain natriuretic peptide in patients with chronic decompensated heart failure

AU - Odom, J. H.

AU - Lowes, B. D.

AU - Crisman, T. S.

AU - Ferguson, D. A.

AU - Wolfel, E. E.

AU - Lindenfeld, J.

AU - Bristow, M. R.

AU - Schrier, R. W.

AU - Abraham, W. T.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The systemic hemodynamic response to a continuous 4-hour infusion of human brain natriuretic peptide (hBNP) was determined in 12 patients with advanced NYHA class III heart failure. Seven patients had ischemic cardiomyopathy, while 5 patients had idiopathic dilated cardiomyopathy. The mean (± SEM) left ventricular ejection fraction for the group was 17 ± 2% (range 14-30%). Patients were evaluated during three 4-hour study periods: baseline, hBNP infusion (0.025 or 0.05 μg/kg/min), and post-treatment (recovery). During the study periods, urinary volume losses were replaced hourly with 0.45% saline solution to separate the vasodilatory and diuretic effects of hBNP. The systemic hemodynamic effects of hBNP in these heart failure patients is shown below (mean±SEM; *p<0.05, **p<0.01 vs. baseline). hBNP 0.025 (n=6) hBNP 0.05 (n=6) Baseline hBNP Recovery Baseline hBNP Recovery RAP (mmHg) 12±2 7±1** 8±1 15±2 10±2* 14±1 PCWP (mmHg) 25±5 12±2** 18±3 29±2 18±3** 24± SVR (d·sec/cm5) 1687±206 1357±160 1737±291 1854±232 1105±193** 1332±198 CI (L/min/m2) 1.96±0.2 2.15±0.2 1.84±0.2 1.68±0.2 2.32±0.3** 2.14±0.3 HR (BPM) 78±6 84±4 86±6 92±5 86±8** 87±9 Conclusion: This first study of a steady-state infusion of hBNP in patients with heart failure demonstrates that hBNP is pharmacologically active and has potential in the treatment of heart failure.

AB - The systemic hemodynamic response to a continuous 4-hour infusion of human brain natriuretic peptide (hBNP) was determined in 12 patients with advanced NYHA class III heart failure. Seven patients had ischemic cardiomyopathy, while 5 patients had idiopathic dilated cardiomyopathy. The mean (± SEM) left ventricular ejection fraction for the group was 17 ± 2% (range 14-30%). Patients were evaluated during three 4-hour study periods: baseline, hBNP infusion (0.025 or 0.05 μg/kg/min), and post-treatment (recovery). During the study periods, urinary volume losses were replaced hourly with 0.45% saline solution to separate the vasodilatory and diuretic effects of hBNP. The systemic hemodynamic effects of hBNP in these heart failure patients is shown below (mean±SEM; *p<0.05, **p<0.01 vs. baseline). hBNP 0.025 (n=6) hBNP 0.05 (n=6) Baseline hBNP Recovery Baseline hBNP Recovery RAP (mmHg) 12±2 7±1** 8±1 15±2 10±2* 14±1 PCWP (mmHg) 25±5 12±2** 18±3 29±2 18±3** 24± SVR (d·sec/cm5) 1687±206 1357±160 1737±291 1854±232 1105±193** 1332±198 CI (L/min/m2) 1.96±0.2 2.15±0.2 1.84±0.2 1.68±0.2 2.32±0.3** 2.14±0.3 HR (BPM) 78±6 84±4 86±6 92±5 86±8** 87±9 Conclusion: This first study of a steady-state infusion of hBNP in patients with heart failure demonstrates that hBNP is pharmacologically active and has potential in the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=33749550431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749550431&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749550431

VL - 44

SP - 149A

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 1

ER -